open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23
Get Citation

Erlotinib in first-line treatment of 70-years old patient with pulmonary adenocarcinoma

Zygmunt Konieczny

open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23

Abstract

Lung cancer is the most frequently cancer in men and the third most frequently type of cancer in women after breast and colon cancer. Lung cancer is the main cause of cancer-related deaths in men and in women too. The majority of patients is diagnosed with advanced stage of disease and the possibility of treatment is limited for palliative or symptomatic care. The introduction targeted molecular therapy in selected groups of patients in stage III and IV with non-small-cell lung cancer (NSCLC) and with activating EGFR gene mutation significantly improve progression free survival (PFS) and quality of life. The tolerance of therapy with tyrosine kinase inhibitors (TKI) is good. Here, a case of 70-years old men with NSCLC (adenocarcinoma) presented classical example qualification, course and tolerance of treatment in therapy with erlotinib.

Abstract

Lung cancer is the most frequently cancer in men and the third most frequently type of cancer in women after breast and colon cancer. Lung cancer is the main cause of cancer-related deaths in men and in women too. The majority of patients is diagnosed with advanced stage of disease and the possibility of treatment is limited for palliative or symptomatic care. The introduction targeted molecular therapy in selected groups of patients in stage III and IV with non-small-cell lung cancer (NSCLC) and with activating EGFR gene mutation significantly improve progression free survival (PFS) and quality of life. The tolerance of therapy with tyrosine kinase inhibitors (TKI) is good. Here, a case of 70-years old men with NSCLC (adenocarcinoma) presented classical example qualification, course and tolerance of treatment in therapy with erlotinib.

Get Citation

Keywords

lung cancer, targeted molecular therapy, erlotinib, TKI

About this article
Title

Erlotinib in first-line treatment of 70-years old patient with pulmonary adenocarcinoma

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. G (2014)

Pages

49-51

Published online

2015-03-23

Keywords

lung cancer
targeted molecular therapy
erlotinib
TKI

Authors

Zygmunt Konieczny

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl